OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
August 24, 2022
Aerie to be purchased by Alcon after recently bringing two glaucoma drugs to market.
August 23, 2022
NICE has recommended the use of Tavneos (avacopan) in combination with rituximab or cyclophosphamide regimen.
Kapruvia (difelikefalin) has been granted approval by Swissmedic as a treatment for moderate-to-severe pruritis associated with CKD.
The European Commission (EC) has approved Celltrion Healthcare's Vegzelma (CT-P16), a biosimilar to bevacizumab referencing Avastin.
The latest CPHI report has been published, predicting that a significant shift in outsourcing strategies is being experienced globally.
EMA has accepted the marketing authorization application for an oral fixed-dose combination treatment as an initial treatment for adults with AML.
August 22, 2022
Grand River Aseptic Manufacturing has completed phase II of its facility expansion with the installation of two new sterile filling lines.
ProBioGen will collobarate with NextPoint Therapeutics to develop and manufacture its lead antibody candidate.
August 16, 2022
Validair Diamond Scientific has installed a new cleanroom for in-house testing, research, and training.
Charles River has received approval to commercially produce allogeneic cell therapy products for distribution in Europe from EMA.